VOYDEYA was studied as an add-on to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) in a randomized, placebo-controlled clinical trial1

In a multiple-region, randomized, double-blind Phase 3 study, adult patients with extravascular hemolysis (EVH)a received either VOYDEYA (n=42) or placebo (n=21) in addition to their stable dose (≥6 months) of ULTOMIRIS or SOLIRIS for 12 weeks.1,2

After 12 weeks, patients on placebo were switched to VOYDEYA and patients in the VOYDEYA arm continued treatment for a total of 24 weeks.1

Study Design graphic

  • A prespecified interim efficacy analysis was performed when 63 patients reached the end of the 12-week treatment period (either completed or discontinued)1,c

  1. a

    EVH was defined as anemia (hemoglobin ≤9.5 g/dL) with absolute reticulocyte count ≥120 x 109/L with or without the need for transfusion.1,3

  2. b

    TP1 treatment allocation remained blinded until interim database lock.2

  3. c

    Discontinuation of VOYDEYA due to an adverse reaction occurred in 5% of patients. Adverse reactions that resulted in permanent discontinuation included 1 patient with blood bilirubin increase and pancreatitis, 1 patient with hepatic enzyme increased, and 1 patient with ALT increased and aspartate aminotransferase increased.1

    4. ALT=alanine aminotransferase; LTE=long-term extension; PNH=paroxysmal nocturnal hemoglobinuria; TP=treatment period.

When VOYDEYA was added to ULTOMIRIS or SOLIRIS…

Patients experienced rapid and sustained improvements in hemoglobin levels1,4,g

The primary endpoint was the change in hemoglobin level from baseline to Week 121,4

Upward arrow showing improvement

(±0.211)h

Patients who took VOYDEYA achieved a statistically significant increase of 2.9 (±0.211)h g/dL in mean hemoglobin levels compared with 0.5 (±0.313) g/dL for placebo (P=0.0007)i at 12 weeks.1,2

Mean change in hemoglobin level over time is considered exploratory in nature. The intermediate visits between baseline and Week 12 were not alpha-controlled.

Patients taking VOYDEYA had a clinically meaningfulj improvement of 2.9 g/dL in hemoglobin at Week 12 compared to 0.5 g/dL with placebo.1,4,5

Improvement in hemoglobin levels through 12 weeks (P=0.0007)1,4,5,i

Clinically meaningfulh improvement of 2.7 g/dL

Clinically meaningful improvement sustained through Week 12

Improvement in hemoglobin levels chart clinical study chart efficacy results

LDH levels remained controlled in both treatment groups through the duration of the clinical trial, indicating continued control of IVH.4,k

When VOYDEYA was added to ULTOMIRIS or SOLIRIS…

Patients had a reduced need for transfusion1

Statistically significant improvements seen at Week 12 in key secondary endpoints1

83.3% n=35/42

of patients were transfusion-free (P=0.0004)

compared with 38.1% of patients (n=8/21) on placebo.1

59.5% n=25/42

of patients had a hemoglobin increase of ≥2 g/dL in the absence of transfusion (P<0.0001)

compared with 0% of patients (n=0/21) on placebo.1,l

35% reduction in absolute reticulocyte count from baseline to Week 12 compared with a 1.5% increase for patients on placebo. The treatment difference for patients on VOYDEYA compared with placebo was -87.2 x 109/L (95% CI: -118, -57) (P<0.0001).1

Patients felt significantly less fatigue at Week 121

Change in FACIT-Fatigue score from baseline to Week 12 (P=0.002)1,2

FACIT-Fatigue chart

Mean change in FACIT-Fatigue for intermediate visits between Week 1 and Week 11 were not alpha-controlled and are exploratory in nature.

A clinically meaningfulm and significant improvement of
8.0 points in FACIT-
Fatigue scores was seen at 12 weeks in patients who took VOYDEYA compared with
1.9 points for patients on placebo. The treatment difference favored VOYDEYA by 6.1 points (95% CI: 2.3, 9.9) (P=0.002).1,4

  • FACIT-Fatigue scores can range from 0 to 52, with higher scores indicating less fatigue1
  • The FACIT-Fatigue score of the general population is on average 43.5 points6

Results at Week 24
were consistent with
those at Week 12, showing increased hemoglobin, transfusion avoidance,
and less fatigue.2

Results at Week 24
were consistent with
those at Week 12, showing increased hemoglobin, transfusion avoidance,
and less fatigue.2

VOYDEYA was well tolerated in clinical studies1,2

The safety profile of VOYDEYA is based on data from a 12-week, multiple-region, randomized, double-blind, placebo-controlled Phase 3 study in which 86 adult patients with PNH received VOYDEYA (n=57) or placebo (n=29) at the recommended dosing regimens as an add-on therapy to ULTOMIRIS or SOLIRIS.1

The most common adverse reaction (≥10%) with VOYDEYA was headache.1

Adverse reactions reported in ≥5% of VOYDEYA-treated patients with PNH and greater than placebo1,n,o

chart-mobile chart

Three patients (5%) treated with VOYDEYA experienced a serious adverse reaction, including pancreatitis, cholecystitis, and increased blood bilirubin.1

When treating with VOYDEYA1:
  • Assess liver enzymes before initiation and periodically during treatment
  • Monitor serum lipids periodically and start cholesterol-lowering medication, if indicated

VOYDEYA demonstrated a favorable benefit-risk profile over 24 weeks, with no deaths or discontinuations due to hemolysis.2,4,q

See how VOYDEYA fits into your patients’ daily routine.

LEARN ABOUT DOSING

gBaseline disease characteristics between the 2 treatment groups were generally balanced and were indicative of EVH.1,2

hData presented as least squares (LS) mean (±standard error [SE]).4

iBased on rerandomization test. The LS mean (±SE) treatment group difference in change from baseline in hemoglobin was 2.4 (±0.375) g/dL (P<0.0001) based on MMRM sensitivity analysis.2

jA change in hemoglobin of ≥2 g/dL is considered clinically meaningful.4

kLDH outcomes were not prespecified and are considered exploratory. All patients were on C5 inhibitor treatment at study entry and had control of IVH (LDH <1.5 x ULN).1

lTransfusion avoidance was considered achieved only by the patients who did not receive a transfusion and did not meet the protocol-specified guidelines for transfusion through the 12-week treatment period.1

mA change in FACIT-Fatigue score of ≥5 points is considered clinically meaningful in PNH.4

nClinically relevant adverse reactions in <5% of patients include increased serum triglycerides.1

oCommon Toxicity Criteria Adverse Events (CTCAE).1

pRepresents a composite of multiple, related adverse reactions.1

qOverall, there were 5 treatment-emergent adverse events of hemolysis (3 hemolysis and 2 breakthrough hemolysis) in 4 participants (all on a stable dose of ULTOMIRIS) based on the clinical judgment of the investigator. None of these events had LDH above 2.2 x ULN.2

CI=confidence interval; FACIT=Functional Assessment of Chronic Illness Therapy; IVH=intravascular hemolysis; LDH=lactate dehydrogenase; MMRM=mixed-effect model for repeated measures; PNH=paroxysmal nocturnal hemoglobinuria; ULN=upper limit of normal.

Important safety
information

IMPORTANT SAFETY INFORMATION FOR VOYDEYA

WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

VOYDEYA, a complement inhibitor, increases the risk of serious
infections, especially those caused by encapsulated bacteria, such as Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B [see Warnings and Precautions (5.1)]. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become
rapidly life-threatening or fatal if not recognized and treated early.

  • Complete or update vaccination for encapsulated bacteria specifically, Neisseria meningitidis and Streptococcus pneumoniae at least 2 weeks prior to the first dose of VOYDEYA, unless the risks
    of delaying therapy with VOYDEYA outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.
    See Warnings and Precautions (5.1) for additional guidance on the management of the risk of serious infections caused by encapsulated bacteria.

  • Patients receiving VOYDEYA are at increased risk for invasive disease
    caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms
    of serious
    infections and evaluate immediately if infection is
    suspected.

Because of the risk of serious infections caused by encapsulated bacteria,
VOYDEYA is available only through a restricted program under
a Risk Evaluation and Mitigation Strategy (REMS) called the VOYDEYA REMS [see Warnings and Precautions (5.2)].

CONTRAINDICATIONS

Initiation in patients with unresolved serious infection caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae type B.

WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria

VOYDEYA, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including Neisseria meningitidis (caused by any serogroup,
including non-groupable strains), Streptococcus pneumoniae, and Haemophilus influenzae type
B. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors.

Complete, update, or revaccinate patients in accordance with ACIP recommendations considering the duration of VOYDEYA therapy. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent VOYDEYA therapy is indicated in a patient who is not up to date with vaccines against encapsulated bacteria according to ACIP recommendations, provide antibacterial drug prophylaxis and administer these vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have
not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including VOYDEYA. The benefits and risks of treatment with VOYDEYA, as well as those associated with antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by encapsulated bacteria.

Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies following vaccination. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if they occur. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of VOYDEYA in patients who are undergoing treatment for serious infections.

VOYDEYA REMS

Due to the risk of serious infections caused by encapsulated bacteria, VOYDEYA is available only through a restricted program called VOYDEYA
REMS. Per the REMS requirements:

Prescribers must enroll in the REMS, counsel patients about the risk of serious infections caused by encapsulated bacteria, provide patients with the REMS educational materials, assess patient vaccination status for vaccines against encapsulated bacteria, and vaccinate if needed according to current ACIP recommendations 2 weeks prior to the first
dose of VOYDEYA. Antibacterial drug prophylaxis must be prescribed if treatment must be started urgently and the patient is not up to date with vaccines against encapsulated bacteria according to current ACIP recommendations at least 2 weeks prior to the first dose of VOYDEYA.

Pharmacies that dispense VOYDEYA must be certified in the VOYDEYA REMS and must verify prescribers are certified.

Patients must receive counseling from the prescriber about the need to
receive vaccinations against encapsulated bacteria per ACIP recommendations, to take antibiotics as directed, the early signs and symptoms of serious infection, and be instructed to carry the Patient Safety Card at all times during and for 1 week following the last dose of VOYDEYA.

Further information is available at www.voydeyarems.com or 1-888-765-4747.

Hepatic Enzyme Increases

Hepatic enzyme elevations have been observed in patients treated with VOYDEYA. A total of
14% of patients receiving VOYDEYA had elevations in serum alanine aminotransferase (ALT). ALT elevations >3× the upper limit of normal (ULN) and ≤5× ULN occurred in 9% of VOYDEYA-treated patients, and ALT elevations >5× ULN and ≤10× ULN occurred in 5% of VOYDEYA-treated patients.

Assess liver enzyme test results prior to the initiation of VOYDEYA and periodically during treatment. Consider treatment interruption or discontinuation if elevations are clinically significant or if the patient becomes symptomatic. VOYDEYA has not been studied in patients with severe hepatic impairment.

Monitoring of PNH Manifestations After VOYDEYA Discontinuation

After discontinuing treatment with VOYDEYA, closely monitor patients for at least 2 weeks after the last dose for signs and symptoms of hemolysis. If discontinuation of VOYDEYA is necessary, continue background treatment
with ravulizumab or eculizumab or consider alternative therapy if necessary. The signs and symptoms of hemolysis may include sudden decrease in hemoglobin or fatigue.

If hemolysis occurs after discontinuation of VOYDEYA, consider restarting treatment with VOYDEYA, if appropriate.

Hyperlipidemia

VOYDEYA increases total cholesterol and LDL-cholesterol. Of the 50
VOYDEYA-treated
patients who had a normal total cholesterol
level at baseline, 30% developed Grade 1 hypercholesterolemia. Of the 6 VOYDEYA-treated patients who had Grade 1 hypercholesterolemia at baseline, 1 patient experienced increased total cholesterol that worsened to Grade 2. Of the 54 VOYDEYA-treated patients who had LDL-cholesterol ≤130 mg/dL at baseline, 13% developed LDL-cholesterol >130-160 mg/dL, and 9% developed LDL-cholesterol >160-190 mg/dL.

Some patients required cholesterol-lowering medications. Monitor serum lipid parameters periodically during treatment with VOYDEYA
and initiate cholesterol-lowering medication, if indicated.

ADVERSE REACTIONS

The most common adverse reaction reported in ≥10% of patients treated with VOYDEYA was headache. Serious adverse reactions were reported in 5% of patients who received VOYDEYA and included pancreatitis, cholecystitis, and increased blood bilirubin. No specific serious adverse reaction was reported in more than 1 patient treated with VOYDEYA. Adverse reactions reported in ≥5% of patients treated with VOYDEYA and greater than placebo in the randomized, controlled period included vomiting, pyrexia, increased alanine aminotransferase, hypertension, and pain in the extremities. Clinically relevant adverse reactions in <5% of patients included increased serum triglycerides.

DRUG INTERACTIONS

BCRP Substrates

Danicopan is a Breast Cancer Resistance Protein (BCRP) inhibitor.
Concomitant use of VOYDEYA with a BCRP substrate increases the plasma concentrations of the BCRP substrate, which may increase the risk for adverse reactions associated with the BCRP substrate.
If used together, monitor patients more frequently for adverse reactions, associated
with the BCRP substrate and consider dose reduction of the BCRP substrate according to
its prescribing information.

Rosuvastatin

Danicopan significantly increased rosuvastatin exposure. The dose of rosuvastatin should not exceed 10mg once daily when concomitantly used
with VOYDEYA.

P-glycoprotein Substrates

Danicopan is an inhibitor of P-glycoprotein (P-gp). Concomitant administration of VOYDEYA with P-gp substrates may increase the plasma concentrations of the P-gp substrates. Dose adjustment might be necessary for P-gp substrates where minimal concentration changes may lead to serious adverse reactions.

USE IN SPECIFIC POPULATIONS

Pregnancy

There are no available data on VOYDEYA use in pregnant individuals to
evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated PNH in pregnancy. The use of VOYDEYA in pregnant women or women planning to become pregnant may be considered following an assessment of the risks and benefits.

Lactation

There are no data on the presence of VOYDEYA in human milk, the effects on the breastfed
child, or the effect on milk production.
VOYDEYA is present in animal milk. When a
drug is present in animal milk, it is likely that the drug will be present in human milk.

Because of the potential for serious adverse reactions in the breastfed child, including serious infections with encapsulated bacteria and liver enzyme increases, advise patients not to breastfeed during treatment with VOYDEYA and for 3 days after the last dose.

Hepatic Impairment

No dose adjustment is required in patients with mild to moderate hepatic impairment. Studies have not been conducted in patients with severe hepatic impairment, therefore, avoid use of VOYDEYA in this patient population.

INDICATION

VOYDEYA is indicated as an add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Limitation of Use:

VOYDEYA has not been shown to be effective
as monotherapy and should only be prescribed
as an add-on to ravulizumab or eculizumab.

To report SUSPECTED ADVERSE REACTIONS, contact Alexion Pharmaceuticals, Inc. at
1-844-259-6783 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for VOYDEYA, including Boxed WARNING
regarding serious and life-threatening or
fatal infections.

IMPORTANT SAFETY INFORMATION FOR ULTOMIRIS

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

ULTOMIRIS, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1)] Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not
recognized and treated early.

  • Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose
    of ULTOMIRIS, unless the risks of delaying ULTOMIRIS therapy outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See Warnings and Precautions (5.1) for additional guidance on the management of the risk of serious infections caused by meningococcal bacteria.

  • Patients receiving ULTOMIRIS are at increased risk for invasive
    disease caused by Neisseria meningitidis, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.

Because of the risk of serious meningococcal infections, ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS [see Warnings and Precautions (5.2)].

CONTRAINDICATIONS

  • Initiation in patients with unresolved serious Neisseria meningitidis infection.

WARNINGS AND PRECAUTIONS

Serious Meningococcal Infections

ULTOMIRIS, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors.

Revaccinate patients in accordance with ACIP recommendations considering the duration of ULTOMIRIS therapy. Note that ACIP
recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent ULTOMIRIS therapy is indicated in a
patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including ULTOMIRIS. The benefits and risks of treatment with ULTOMIRIS, as well as those associated with antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by Neisseria meningitidis.

Vaccination does not eliminate the risk of serious meningococcal
infections, despite development of antibodies following vaccination.

Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if they occur. Promptly treat known infections. Meningococcal
infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of ULTOMIRIS in
patients who are undergoing treatment for serious meningococcal infection depending on the risks of interrupting treatment in the disease being treated.

ULTOMIRIS and SOLIRIS REMS

Due to the risk of serious meningococcal infections, ULTOMIRIS is available only through
a restricted program called ULTOMIRIS and SOLIRIS REMS.

Prescribers must enroll in the REMS, counsel patients about the risk of serious meningococcal infection, provide patients with the REMS educational materials, assess patient vaccination status for meningococcal vaccines (against serogroups A, C, W, Y, and B) and vaccinate if needed according to current ACIP recommendations two weeks prior to the first dose of ULTOMIRIS. Antibacterial drug prophylaxis must be prescribed if treatment must be started urgently, and the patient is not up to date with both meningococcal vaccines according to current ACIP recommendations at least two weeks prior to the first dose of ULTOMIRIS. Patients must receive counseling about the need to receive meningococcal vaccines and to take antibiotics as directed, signs and symptoms of meningococcal infection, and be instructed to carry the Patient Safety Card at all times during and for 8 months following ULTOMIRIS treatment.

Further information is available at www.UltSolREMS.com or
1-888-765-4747.

Other Infections

Serious infections with Neisseria species (other than Neisseria meningitidis), including disseminated gonococcal infections, have been reported.

ULTOMIRIS blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections caused by Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Children treated with ULTOMIRIS may be at increased risk of developing serious infections due to Streptococcus pneumoniae
and Haemophilus influenzae type b (Hib). Administer vaccinations for the prevention of Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) infections according to ACIP recommendations. Patients receiving ULTOMIRIS are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination.

Monitoring Disease Manifestations after ULTOMIRIS Discontinuation

After discontinuing treatment with ULTOMIRIS, closely monitor for signs
and symptoms of hemolysis, identified by elevated LDH along with sudden decrease in PNH clone size or hemoglobin, or re-appearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, shortness of breath (dyspnea), major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues ULTOMIRIS
for at
least 16 weeks to detect hemolysis and other reactions. If signs and symptoms of hemolysis occur after discontinuation, including elevated LDH, consider restarting treatment with ULTOMIRIS.

Thromboembolic Event Management

The effect of withdrawal of anticoagulant therapy during treatment with ULTOMIRIS has
not been established. Treatment should not
alter anticoagulant management.

Infusion-Related Reactions

Intravenous administration may result in systemic infusion-related
reactions, including
anaphylaxis and hypersensitivity reactions. In clinical trials, infusion-related reactions
occurred in approximately 1 to 7% of patients treated with ULTOMIRIS. These events included lower back pain, drop in blood pressure, limb discomfort, drug hypersensitivity (allergic reaction), dysgeusia (bad taste), and drowsiness. These reactions did not require discontinuation of ULTOMIRIS. If signs of cardiovascular instability or respiratory compromise occur, interrupt ULTOMIRIS
infusion and institute appropriate supportive measures.

ADVERSE REACTIONS

Adverse reactions reported in ≥10% or more of patients with PNH were upper respiratory tract infection and headache. Serious adverse reactions were reported in 15 (6.8%) patients receiving ULTOMIRIS. The serious adverse reactions in patients treated with ULTOMIRIS included
hyperthermia and pyrexia. No serious adverse reaction was reported in
more than 1 patient treated with ULTOMIRIS. One fatal case of sepsis was identified in a patient treated with ULTOMIRIS. In clinical studies, clinically relevant adverse reactions in 1% of adult patients
include infusion-related reactions.

Adverse reactions reported in ≥10% of pediatric patients treated with ULTOMIRIS who were treatment-naïve vs. Eculizumab-experienced were anemia (20% vs. 25%), abdominal pain (0% vs. 38%), constipation (0% vs. 25%), pyrexia (20% vs. 13%), upper respiratory tract infection (20% vs. 75%), pain in extremity (0% vs. 25%), and headache (20% vs. 25%).

DRUG INTERACTIONS

Plasma Exchange, Plasmapheresis, and Intravenous Immunoglobulins

Concomitant use of ULTOMIRIS with plasma exchange (PE),
plasmapheresis (PP), or intravenous immunoglobulin (IVIg) treatment can reduce serum ravulizumab concentrations and requires a supplemental dose of ULTOMIRIS.

Neonatal Fc Receptor Blockers

Concomitant use of ULTOMIRIS with neonatal
Fc receptor (FcRn) blockers (e.g., efgartigimod) may lower systemic exposures and reduce
effectiveness of ULTOMIRIS. Closely monitor
for reduced effectiveness of ULTOMIRIS.

INDICATION

ULTOMIRIS is indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).

To report SUSPECTED ADVERSE REACTIONS, contact Alexion Pharmaceuticals, Inc. at
1-844-259-6783 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

References: 1. VOYDEYA. Prescribing information. Alexion Pharmaceuticals, Inc. 2. Data on file. Alexion Pharmaceuticals, Inc. 3. Kulasekararaj A, Mellor J, Earl L, et al. PB2056: prevalence of clinically significant extravascular hemolysis in stable C5 inhibitor-treated patients with PNH and its association with disease control, quality of life and treatment satisfaction. Hemasphere. 2023;7(suppl 3):e35238f0. 4. Lee JW, Griffin M, Kim JS, et al. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. Lancet Haematol. 2023;10(12):e955-e965. 5. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of
hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004;15(6):979-986. 6. Montan I, Löwe B, Cella D, Mehnert A, Hinz A. General population norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale. Value Health. 2018;21(11):1313-1321.